Sirolimus Shortage Update: What Patients Need to Know in 2026

If you rely on sirolimus (Rapamune) for kidney transplant rejection prevention or for treating lymphangioleiomyomatosis (LAM), you may have noticed that filling your prescription isn't always straightforward. Concerns about drug shortages are understandably stressful when the stakes involve a transplanted organ.

Here's a comprehensive update on sirolimus availability in 2026, including what's driving any access challenges, what the official shortage status is, and what you can do to protect yourself.

Current Sirolimus Shortage Status (2026)

As of early 2026, sirolimus is not listed on an active formal shortage by the FDA's Drug Shortage Staff or the American Society of Health-System Pharmacists (ASHP). This is a positive development compared to some periods in recent years when transplant drugs faced more significant supply disruptions.

Generic sirolimus is now manufactured by multiple companies, including Zydus, Amneal, Teva, and Glenmark. This generic competition has improved the overall supply resilience compared to when only brand Rapamune was available.

Why Patients Still Struggle to Find Sirolimus

Even without a formal shortage, many patients report difficulty finding sirolimus at their local pharmacy. This is because "no shortage" means there's enough drug in the overall supply — not that every pharmacy has it on the shelf right now. Several factors contribute:

• Specialty drug stocking: Sirolimus is a specialty medication with relatively low prescription volume. Most retail pharmacies don't keep it on shelves and order it on demand.
• Formulation gaps: Some strengths (particularly the oral solution and 0.5 mg tablets) are harder to source than 1 mg tablets. Your pharmacy might have one strength but not another.
• Regional distribution variation: Supply distribution isn't uniform across the country. Pharmacies in areas with fewer transplant centers may order sirolimus less frequently.
• Insurance specialty requirements: Some insurance plans require sirolimus to be dispensed by a specialty pharmacy, which may take longer to set up if you're new to the medication.

Historical Context: Has Sirolimus Been in Shortage Before?

Sirolimus, like many specialty medications, has experienced periods of localized supply strain in the past. The broader context of immunosuppressant shortages became more acute during the COVID-19 pandemic when global supply chains were severely disrupted. Several transplant drugs faced intermittent supply issues between 2020 and 2023.

The entry of multiple generic manufacturers since then has been a stabilizing force. However, complex medications like sirolimus require specialized manufacturing, and any disruption at key production facilities can send ripples through the supply chain.

What Transplant Patients Should Do Right Now

Whether or not there's an official shortage, here are the steps every sirolimus patient should take to protect their medication supply:

1. Refill 7–10 days early. Don't wait until your last dose. Specialty medications can take several days to be ordered and received at a retail pharmacy.
2. Switch to a specialty or mail-order pharmacy. These pharmacies stock sirolimus reliably and can supply 90-day fills, reducing how often you have to manage refills.
3. Know your transplant coordinator's contact info. If you cannot find sirolimus within 24 hours of running low, call your transplant team. They can often arrange emergency dispensing.
4. Use medfinder to search nearby pharmacies. medfinder contacts pharmacies near you to check who has sirolimus in stock right now, saving you hours of calls.

What LAM Patients Should Know

Sirolimus is the only FDA-approved oral treatment for lymphangioleiomyomatosis as of 2026. Patients with LAM may be prescribed lower doses than transplant patients (typically 2 mg/day, adjusted by blood levels), and the medication is just as essential for disease management. LAM patients should apply the same early-refill and specialty-pharmacy strategies outlined above.

The LAM Foundation (thelamfoundation.org) is an excellent resource for patient support and may have current information on sirolimus availability specifically for LAM patients.

Will the Shortage Get Better or Worse?

The overall outlook for sirolimus availability is cautiously optimistic. Multiple generic manufacturers have entered the market over the past several years, providing redundancy in the supply chain. The sirolimus market is also growing — driven by expanded uses in oncology, drug-eluting stent technology, and ongoing research into its potential longevity and antiaging effects — which incentivizes manufacturers to maintain consistent production.

However, drug supply chains can change rapidly. The best protection against any future disruption is to maintain a buffer supply of at least 7–10 days, keep your specialty pharmacy contact information handy, and stay in communication with your transplant team.

Summary

Sirolimus is not in a formal national shortage in 2026, but it's still a specialty medication that requires planning to fill consistently. Use early refill strategies, specialty pharmacies, and medfinder to minimize access disruptions. For hands-on help finding it, read our

step-by-step guide to finding sirolimus in stock